ALBENDAZOLE TABLETS 200MG
ALBENDAZOLE TABLETS USP 200 MG
COMPOSITION
- Each Chewable Tablet contains,
- Albendazole USP 200 mg
- Excipients Q.S.
PHARMACOLOGICAL ACTION
Pharmacodynamic properties Albendazole is a benzimidazolecarbamate with anthelmintic and antiprotozoal activity against intestinal and tissue parasites Animal studies have shown that albendazole exhibits vermicidal, ovacidal and larvacidal activity and exerts its anthelmintic effect by inhibiting tubulin polymerization. This causes the disruption of the helminth metabolism, including energy depletion, which immobilises and then kills the susceptible helminth.
PHARMACOKINETIC PROPERTIES
In man, after oral administration, albendazole is absorbed and completely metabolised.
At a dose of 6, 6 mg/kg of albendazole the plasma concentration of itsmain metabolite, the sulfoxide, attains a maximum of 0,25 to 0,30 µg/ml after approximately 2½ hours.
The half-life of the sulfoxide in the plasma is 8½ hours. The metabolite is essentially eliminated via the urine.
At a dose of 6, 6 mg/kg of albendazole the plasma concentration of itsmain metabolite, the sulfoxide, attains a maximum of 0,25 to 0,30 µg/ml after approximately 2½ hours.
The half-life of the sulfoxide in the plasma is 8½ hours. The metabolite is essentially eliminated via the urine.
INDICATIONS
It is indicated in the treatment of single or mixed intestinal parasites including Ascarislumbricoides (roundworm), Trichuristrichiura (whipworm), Enterobiusvermicularis (pinworm / threadworm), Ancylostomaduodenale and Necatoramericanus (hookworm), Taenia spp. (tapeworm) and Strong yloidesstercoralis. It has been shown to be effective in the treatment of Giardia (duodenalis or intestinalis or lamblia) infections in children.
CONTRA-INDICATIONS
Pregnancy and lactation are contra-indicated in patients with a known history of hypersensitivity to albendazole or constituents of this medicine.
WARNINGS AND SPECIAL PRECAUTIONS
Leucopenia may occur when it is used for periods longer than recommended.
In order to avoid administering Albendazole during early pregnancy, women of childbearing age should initiate reatment during the first week of menstruation or after a negative pregnancy test.
Sub-clinical neurocystercosis may manifest after a single dose of Albendazole.
Treatment with albendazole may uncover pre-existing neurocysticercosis, particularly in areas with high taenosis infection.
Patients may experience neurological symptoms e.g. seizures, increased intracranial pressure and focal signs as a result of aninflammatory reaction caused by death of the parasite within the brain. Symptoms may occur soon after treatment, appropriate steroid and anticonvulsant therapy should be started immediately.
Patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose-galactosemalabsorption should not take this medicine.
In order to avoid administering Albendazole during early pregnancy, women of childbearing age should initiate reatment during the first week of menstruation or after a negative pregnancy test.
Sub-clinical neurocystercosis may manifest after a single dose of Albendazole.
Treatment with albendazole may uncover pre-existing neurocysticercosis, particularly in areas with high taenosis infection.
Patients may experience neurological symptoms e.g. seizures, increased intracranial pressure and focal signs as a result of aninflammatory reaction caused by death of the parasite within the brain. Symptoms may occur soon after treatment, appropriate steroid and anticonvulsant therapy should be started immediately.
Patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose-galactosemalabsorption should not take this medicine.
